Novel Method Combines Heart Biopsy and Device Implantation to Reduce Risk of Complications and Support Early Diagnosis of Heart Conditions

Endomyocardial biopsy (EMB) is a valuable method for diagnosing a range of cardiac conditions, but there is a risk of complication due to its invasive nature. Researchers have now found a way to combine right ventricular (RV) septal EMB, exploiting the benefit of 3D curved conduction system pacing (CSP) sheaths, with subsequent cardiac implantable electronic device (CIED, devices like pacemakers or defibrillators to regulate heart rhythm) implantation, using the same sheath. Two articles in Heart Rhythm 打開新的分頁／視窗, the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society, and the Pediatric & Congenital Electrophysiology Society, published by Elsevier, demonstrate the feasibility and safety of this novel method.

EMB carries a complication risk of up to 3%. It is usually performed only when noninvasive methods fail to provide a definitive diagnosis or necessary histology, which may lead to diagnostic delays. This novel streamlined process reduces the risk of complications. It also allows doctors to diagnose heart conditions like cardiomyopathy and heart failure earlier, enabling them to start treatment sooner, which can improve the patient's outcome. Additionally, early diagnosis can help identify genetic causes of the heart condition, which can benefit other family members.

John Silberbauer, MA, MD(Res), FRCP, Sussex Cardiac Centre, Brighton, UK, first author of the accompanying editorial commentary "Pace and Biopsy 打開新的分頁／視窗," explains, "Improving the ease, diagnostic yield, and the safety profile of EMB may enable earlier diagnosis and treatment of a range of cardiac conditions, bringing us closer to how other medical specialties manage tissue diagnoses. The two articles in Heart Rhythm detail the researchers' experiences in combining RV septal EMB, exploiting the benefit of 3D CSP sheaths, with subsequent CIED implantation, using the same sheath. The use of these novel CSP sheaths allowed more accurate and upfront RV septal apposition, making concomitant biopsy a quick and safe add-on to the planned device implantation."

Lead investigator Kenji Kuroki, MD, Department of Cardiovascular Medicine, University of Yamanashi, Chuo, Japan, says, "Our study "Novel technique and assessment of available 3-dimensional delivery  打開新的分頁／視窗

sheath for endomyocardial biopsy during cardiac device implantation 打開新的分頁／視窗" demonstrated the usefulness and safety of the new method for performing EMB in 20 patients using a 3-dimensional delivery sheath during CIED implantation. Additionally, it enabled the early diagnosis of previously undetected cardiac amyloidosis (CA) in 4 patients (20%), as confirmed by pathologic findings. Subclinical CA may often be overlooked among patients with CIED implantation. Early diagnosis could enable the timely initiation of appropriate treatment, making this finding particularly important."

Patients for whom CIED is indicated can face complications like cardiomyopathy or other unspecified cardiac abnormalities and may need EMB. However, EMB by a bioptome, a tool to extract tissue samples from the heart, is usually avoided to reduce the risk of lead displacement in the CIED peri-procedural period, following EMB guidelines.

In the study "Feasibility and safety of endomyocardial biopsy by lumenless pacing lead sheath–directed method during cardiac implantable electronic device implantation 打開新的分頁／視窗," 80 patients referred for EMB were enrolled to assess the safety and feasibility of a novel approach for transvenous RV EMB using the lead sheath method (L-S-M) during CIED implantation, comparing it with the traditional bioptome method (T-B-M).

Lead investigator Yang Ye, MD, PhD, Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China, notes, "Using cardiac pacing leads instead of traditional myocardial biopsy forceps during the implantation could be timesaving and cost-effective without compromising safety. In addition, it has the advantages of requiring only one vessel for both EMB and CIED implantation. In this study, no ventricular perforations or serious cardiac event occurred, demonstrating a safe L-S-M procedure of EMB."

Coauthor of the study Guosheng Fu, MD, PhD, Department of Cardiology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China, adds, “Our study demonstrated that RV EMB by the innovative L-S-M method is technically feasible and safe, and able to yield valuable and early diagnosis for patients who are candidates for CIEDs as well as being cost-effective without needing extra tools for EMB."

Dr. Silberbauer concludes, "These two studies demonstrate that opportunistic EMB is feasible and safe using fixed 3D curved CSP sheaths that are designed to reach the RV septum. In selected patients requiring CIED, this method may, in the future, enable a more definitive and earlier diagnosis for patients with cardiomyopathies and heart failure, which may facilitate earlier instigation of prognosis-modifying therapies, genetic testing, and cascade screening. The big questions will be, for whom is ‘pace and biopsy’ the right approach, who is qualified to do it, and where will this novel approach lead us?"

Notes for editors

The articles are:

“Novel technique and assessment of available 3-dimensional delivery sheath for endomyocardial biopsy during cardiac device implantation," by Koji Sudo, MD, Kenji Kuroki, MD, Kazuto Nakamura, MD, Yosuke Watanabe, MD, Manabu Uematsu, MD, Chisa Asahina, MD, Yuya Tanaka, MD, Tsuyoshi Kobayashi, MD, and Akira Sato, MD (https://doi.org/10.1016/j.hrthm.2024.10.069 打開新的分頁／視窗). It is openly available at https://www.heartrhythmjournal.com/article/S1547-5271(24)03534-3/fulltext 打開新的分頁／視窗.

Journalists wishing to interview the authors should contact Kenji Kuroki, MD, at [email protected] 打開新的分頁／視窗.

“Feasibility and safety of endomyocardial biopsy by lumenless pacing lead sheath–directed method during cardiac implantable electronic device implantation," by Yang Ye, MD, PhD, FHRS, Youyou Chen, MD, Hao Jiang, MD, Jiling Zeng, MD, Xingchen Wang, MD, Ying Yang, MD, PhD, Xiang Lan Liu, MD, PhD, XuLin Hong, MD, PhD, Bei Wang, MD, Ya Xun Sun, MD, PhD, Dongwu Lai, MD, PhD, Xi-qi Xu, MD, PhD, and Guo-sheng Fu, MD, PhD (https://doi.org/10.1016/j.hrthm.2024.11.018 打開新的分頁／視窗). It is openly available for 30 days at https://www.heartrhythmjournal.com/article/S1547-5271(24)03571-9/fulltext 打開新的分頁／視窗.

Journalists wishing to interview the authors should contact Yang Ye, MD, PhD, FHRS, at [email protected] 打開新的分頁／視窗.

The editorial commentary is "Pace and Biopsy," by John Silberbauer, MA, MD(Res), FRCP, Christopher Pavitt, MD, MRCP, Alexander Liu, MD, MRCP, and Christopher Bruce, MBChB, MRCP (https://doi.org/10.1016/j.hrthm.2024.11.049 打開新的分頁／視窗). It is openly available for 30 days at https://www.heartrhythmjournal.com/article/S1547-5271(24)03633-6/fulltext 打開新的分頁／視窗.

Journalists wishing to interview the authors should contact John Silberbauer, MA, MD(Res), FRCP, at [email protected] 打開新的分頁／視窗.

The articles appear online in advance of Heart Rhythm, volume 22, Issue 4 (April 2025), published by Elsevier.

Full text of the articles is also available to credentialed journalists upon request; contact Jane Grochowski at +1 406 542 8397 or [email protected] 打開新的分頁／視窗.

About Heart Rhythm

Heart Rhythm 打開新的分頁／視窗, the official Journal of the Heart Rhythm Society 打開新的分頁／視窗, the Cardiac Electrophysiology Society 打開新的分頁／視窗, and the Pediatric & Congenital Electrophysiology Society 打開新的分頁／視窗, is a unique journal for fundamental discovery and clinical applicability. It integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community. www.heartrhythmjournal.com 打開新的分頁／視窗

About the Heart Rhythm Society

The Heart Rhythm Society 打開新的分頁／視窗 is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal healthcare policies and standards. The Heart Rhythm Society is the preeminent professional group representing more than 8,000 specialists in cardiac pacing and electrophysiology from more than 94 countries. www.HRsonline.org 打開新的分頁／視窗

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,500 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundation 打開新的分頁／視窗) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELX 打開新的分頁／視窗 的一部分，RELX 打開新的分頁／視窗 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。